Bio-Techne
$72.40Change from previous close: 0.00%
At a glance
- Revenue growth
- −0.38%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +147.77%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 15.0%
- FY to Jun 2025: 6.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 321 | 311 | 296 | 287 | 317 |
| Cost of revenue | 110 | 103 | 105 | 98.4 | 118 |
| Gross profit | 211 | 208 | 191 | 188 | 199 |
| Selling, general and administrative | 67.4 | 109 | 114 | 116 | 23.2 |
| Research and development | 23.9 | 23.5 | 23.1 | 24.2 | 26.0 |
| Operating income | 95.0 | 75.5 | 54.5 | 47.7 | 117 |
| EBIT | 72.8 | 73.6 | 53.0 | 50.9 | -20.7 |
| EBITDA | 96.9 | 97.8 | 77.7 | 75.3 | 6.4 |
| Interest expense | 2.1 | 2.4 | 2.2 | 2.9 | 2.2 |
| Pre-tax income | 70.7 | 71.2 | 50.8 | 48.0 | -22.9 |
| Income tax | 16.1 | 20.2 | 12.8 | 9.8 | -5.2 |
| Net income | 54.6 | 51.0 | 38.0 | 38.2 | -17.7 |
| Net income to common shareholders | 54.6 | 51.0 | 38.0 | 38.2 | -17.7 |
| Basic EPS | 0.35 | 0.33 | 0.24 | 0.25 | -0.11 |
| Diluted EPS | 0.35 | 0.32 | 0.24 | 0.24 | -0.11 |
| Average shares (basic) | 156 | 156 | 156 | 155 | 155 |
| Average shares (diluted) | 157 | 157 | 157 | 156 | 156 |